Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
1.300
+0.036 (2.88%)
At close: May 20, 2025, 4:00 PM
1.290
-0.010 (-0.74%)
After-hours: May 20, 2025, 7:03 PM EDT

Akari Therapeutics, Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
8.679.6611.3613.538.089.16
Upgrade
Research & Development
5.526.985.459.569.138.82
Upgrade
Operating Expenses
14.1816.6516.8123.0917.2117.98
Upgrade
Operating Income
-14.18-16.65-16.81-23.09-17.21-17.98
Upgrade
Interest Expense
-0.3-0.24----
Upgrade
Interest & Investment Income
0.010.010.080.050.010.01
Upgrade
Currency Exchange Gain (Loss)
0.110.010.140.45-0.190.35
Upgrade
Other Non Operating Income (Expenses)
1.382.086.584.84-0.030.53
Upgrade
EBT Excluding Unusual Items
-12.99-14.8-10.01-17.75-17.42-17.08
Upgrade
Merger & Restructuring Charges
-5-5----
Upgrade
Other Unusual Items
0.05-----
Upgrade
Pretax Income
-17.93-19.79-10.01-17.75-17.42-17.08
Upgrade
Net Income
-17.93-19.79-10.01-17.75-17.42-17.08
Upgrade
Net Income to Common
-17.93-19.79-10.01-17.75-17.42-17.08
Upgrade
Shares Outstanding (Basic)
17125322
Upgrade
Shares Outstanding (Diluted)
17125322
Upgrade
Shares Change (YoY)
202.84%144.03%56.79%45.46%35.87%72.53%
Upgrade
EPS (Basic)
-1.05-1.66-2.04-5.69-8.12-10.81
Upgrade
EPS (Diluted)
-1.05-1.66-2.04-5.69-8.12-20.00
Upgrade
Free Cash Flow
-10.66-12.55-16.43-21.5-18.85-16.95
Upgrade
Free Cash Flow Per Share
-0.62-1.05-3.36-6.89-8.78-10.73
Upgrade
EBITDA
-14.18-16.63-16.8-23.08-17.21-17.97
Upgrade
D&A For EBITDA
00.010000.01
Upgrade
EBIT
-14.18-16.65-16.81-23.09-17.21-17.98
Upgrade
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q